Investigation of the Efficacy of Quinine Sulphate Administered Via Taste-Masked Pellets to Children With Falciparum Malaria
NCT ID: NCT00329134
Last Updated: 2009-04-17
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE2
56 participants
INTERVENTIONAL
2006-07-31
2007-05-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
At this moment, quinine sulphate pellets are developed. These pellets enable an adequate dosing according to the body weight.
56 children with malaria will be dosed every 8 hours during 7 days with 10-15mg/kg body weight.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Chloroquine and Amodiaquine for Treatment of Malaria in Children
NCT00137514
The Effect of Paracetamol in the Treatment of Non-severe Malaria in Children in Guinea-Bissau
NCT00137566
Treatment of Malaria With Quinine Plus Sulfadoxine-Pyrimethamine
NCT00167739
Parenteral Artesunate Compared to Quinine as a Cause of Late Anaemia in African Children With Malaria
NCT02092766
Efficacy of Amodiaquine in the Treatment of Uncomplicated Falciparum Malaria in Young Children of Burkina Faso
NCT00261222
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
SINGLE_GROUP
TREATMENT
NONE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Administration of quinine sulphate taste-masked pellets
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Informed consent
Exclusion Criteria
6 Months
59 Months
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University Ghent
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
University Ghent
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Luc Van Bortel, MD, PhD
Role: PRINCIPAL_INVESTIGATOR
University Hospital, Ghent
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Centre Hospitalier De Butare
Butare, , Rwanda
Countries
Review the countries where the study has at least one active or historical site.
Related Links
Access external resources that provide additional context or updates about the study.
Website University Hospital Ghent
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2006/177
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.